COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients.
<h4>Background</h4>The COVID-19 pandemic remains a significant global threat. However, despite urgent need, there remains uncertainty surrounding best practices for pharmaceutical interventions to treat COVID-19. In particular, conflicting evidence has emerged surrounding the use of hydr...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0248128&type=printable |
| _version_ | 1826554292167770112 |
|---|---|
| author | Mark Stewart Carla Rodriguez-Watson Adem Albayrak Julius Asubonteng Andrew Belli Thomas Brown Kelly Cho Ritankar Das Elizabeth Eldridge Nicolle Gatto Alice Gelman Hanna Gerlovin Stuart L Goldberg Eric Hansen Jonathan Hirsch Yuk-Lam Ho Andrew Ip Monika Izano Jason Jones Amy C Justice Reyna Klesh Seth Kuranz Carson Lam Qingqing Mao Samson Mataraso Robertino Mera Daniel C Posner Jeremy A Rassen Anna Siefkas Andrew Schrag Georgia Tourassi Andrew Weckstein Frank Wolf Amar Bhat Susan Winckler Ellen V Sigal Jeff Allen |
| author_facet | Mark Stewart Carla Rodriguez-Watson Adem Albayrak Julius Asubonteng Andrew Belli Thomas Brown Kelly Cho Ritankar Das Elizabeth Eldridge Nicolle Gatto Alice Gelman Hanna Gerlovin Stuart L Goldberg Eric Hansen Jonathan Hirsch Yuk-Lam Ho Andrew Ip Monika Izano Jason Jones Amy C Justice Reyna Klesh Seth Kuranz Carson Lam Qingqing Mao Samson Mataraso Robertino Mera Daniel C Posner Jeremy A Rassen Anna Siefkas Andrew Schrag Georgia Tourassi Andrew Weckstein Frank Wolf Amar Bhat Susan Winckler Ellen V Sigal Jeff Allen |
| author_sort | Mark Stewart |
| collection | DOAJ |
| description | <h4>Background</h4>The COVID-19 pandemic remains a significant global threat. However, despite urgent need, there remains uncertainty surrounding best practices for pharmaceutical interventions to treat COVID-19. In particular, conflicting evidence has emerged surrounding the use of hydroxychloroquine and azithromycin, alone or in combination, for COVID-19. The COVID-19 Evidence Accelerator convened by the Reagan-Udall Foundation for the FDA, in collaboration with Friends of Cancer Research, assembled experts from the health systems research, regulatory science, data science, and epidemiology to participate in a large parallel analysis of different data sets to further explore the effectiveness of these treatments.<h4>Methods</h4>Electronic health record (EHR) and claims data were extracted from seven separate databases. Parallel analyses were undertaken on data extracted from each source. Each analysis examined time to mortality in hospitalized patients treated with hydroxychloroquine, azithromycin, and the two in combination as compared to patients not treated with either drug. Cox proportional hazards models were used, and propensity score methods were undertaken to adjust for confounding. Frequencies of adverse events in each treatment group were also examined.<h4>Results</h4>Neither hydroxychloroquine nor azithromycin, alone or in combination, were significantly associated with time to mortality among hospitalized COVID-19 patients. No treatment groups appeared to have an elevated risk of adverse events.<h4>Conclusion</h4>Administration of hydroxychloroquine, azithromycin, and their combination appeared to have no effect on time to mortality in hospitalized COVID-19 patients. Continued research is needed to clarify best practices surrounding treatment of COVID-19. |
| first_indexed | 2024-12-13T22:01:48Z |
| format | Article |
| id | doaj.art-54f31913ca1947ed9d201427eb11393b |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2025-03-14T07:38:35Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-54f31913ca1947ed9d201427eb11393b2025-03-03T05:36:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01163e024812810.1371/journal.pone.0248128COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients.Mark StewartCarla Rodriguez-WatsonAdem AlbayrakJulius AsubontengAndrew BelliThomas BrownKelly ChoRitankar DasElizabeth EldridgeNicolle GattoAlice GelmanHanna GerlovinStuart L GoldbergEric HansenJonathan HirschYuk-Lam HoAndrew IpMonika IzanoJason JonesAmy C JusticeReyna KleshSeth KuranzCarson LamQingqing MaoSamson MatarasoRobertino MeraDaniel C PosnerJeremy A RassenAnna SiefkasAndrew SchragGeorgia TourassiAndrew WecksteinFrank WolfAmar BhatSusan WincklerEllen V SigalJeff Allen<h4>Background</h4>The COVID-19 pandemic remains a significant global threat. However, despite urgent need, there remains uncertainty surrounding best practices for pharmaceutical interventions to treat COVID-19. In particular, conflicting evidence has emerged surrounding the use of hydroxychloroquine and azithromycin, alone or in combination, for COVID-19. The COVID-19 Evidence Accelerator convened by the Reagan-Udall Foundation for the FDA, in collaboration with Friends of Cancer Research, assembled experts from the health systems research, regulatory science, data science, and epidemiology to participate in a large parallel analysis of different data sets to further explore the effectiveness of these treatments.<h4>Methods</h4>Electronic health record (EHR) and claims data were extracted from seven separate databases. Parallel analyses were undertaken on data extracted from each source. Each analysis examined time to mortality in hospitalized patients treated with hydroxychloroquine, azithromycin, and the two in combination as compared to patients not treated with either drug. Cox proportional hazards models were used, and propensity score methods were undertaken to adjust for confounding. Frequencies of adverse events in each treatment group were also examined.<h4>Results</h4>Neither hydroxychloroquine nor azithromycin, alone or in combination, were significantly associated with time to mortality among hospitalized COVID-19 patients. No treatment groups appeared to have an elevated risk of adverse events.<h4>Conclusion</h4>Administration of hydroxychloroquine, azithromycin, and their combination appeared to have no effect on time to mortality in hospitalized COVID-19 patients. Continued research is needed to clarify best practices surrounding treatment of COVID-19.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0248128&type=printable |
| spellingShingle | Mark Stewart Carla Rodriguez-Watson Adem Albayrak Julius Asubonteng Andrew Belli Thomas Brown Kelly Cho Ritankar Das Elizabeth Eldridge Nicolle Gatto Alice Gelman Hanna Gerlovin Stuart L Goldberg Eric Hansen Jonathan Hirsch Yuk-Lam Ho Andrew Ip Monika Izano Jason Jones Amy C Justice Reyna Klesh Seth Kuranz Carson Lam Qingqing Mao Samson Mataraso Robertino Mera Daniel C Posner Jeremy A Rassen Anna Siefkas Andrew Schrag Georgia Tourassi Andrew Weckstein Frank Wolf Amar Bhat Susan Winckler Ellen V Sigal Jeff Allen COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. PLoS ONE |
| title | COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. |
| title_full | COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. |
| title_fullStr | COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. |
| title_full_unstemmed | COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. |
| title_short | COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients. |
| title_sort | covid 19 evidence accelerator a parallel analysis to describe the use of hydroxychloroquine with or without azithromycin among hospitalized covid 19 patients |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0248128&type=printable |
| work_keys_str_mv | AT markstewart covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT carlarodriguezwatson covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT ademalbayrak covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT juliusasubonteng covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT andrewbelli covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT thomasbrown covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT kellycho covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT ritankardas covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT elizabetheldridge covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT nicollegatto covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT alicegelman covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT hannagerlovin covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT stuartlgoldberg covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT erichansen covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT jonathanhirsch covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT yuklamho covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT andrewip covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT monikaizano covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT jasonjones covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT amycjustice covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT reynaklesh covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT sethkuranz covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT carsonlam covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT qingqingmao covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT samsonmataraso covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT robertinomera covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT danielcposner covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT jeremyarassen covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT annasiefkas covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT andrewschrag covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT georgiatourassi covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT andrewweckstein covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT frankwolf covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT amarbhat covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT susanwinckler covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT ellenvsigal covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients AT jeffallen covid19evidenceacceleratoraparallelanalysistodescribetheuseofhydroxychloroquinewithorwithoutazithromycinamonghospitalizedcovid19patients |